ArticleCureus2025
Comparison of Three Potassium Binders in Patients With Acute Hyperkalemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperkalemia is a common electrolyte abnormality that can occur in hospitalized patients, particularly those with chronic kidney disease. If not appropriately treated, hyperkalemia can result in life-threatening arrhythmias. While sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate (SZC) are widely used potassium binders, no study has compared all three binders in lowering potassium in acute hyperkalemia in the acute care setting.
objectiveThe primary outcome was the post-treatment change in serum potassium concentration, compared by binder, within 24 hours.
methodsThis retrospective cohort quality improvement project included 75 adult inpatients who received SPS, SZC, or patiromer at a community teaching hospital between 2021 and 2023.
resultsAll three potassium binders showed a statistically significant difference in lowering potassium concentrations within 24 hours (p<0.001). Controlling for baseline potassium, standard of care, and BMI, SPS and SZC were superior to patiromer (p=0.001 and p=0.022, respectively). There was no statistically significant difference between SPS and SZC (p=0.206).
conclusionSPS and SZC were superior to patiromer in lowering serum potassium levels in patients with acute hyperkalemia, with no significant difference between SPS and SZC. Considering the established safety concerns associated with SPS, SZC may be the preferred binder for managing acute hyperkalemia in the inpatient setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.